![CNS relapse. (A) The 12-month cumulative risk of CNS relapse after CNS-BRT and CART was 25.0% (95% CI, 6-52). (B) Images showing the CNS-BRT treatment plans to the 50% isodose line. Patient 1: sagittal postcontrast computed tomography (CT) of the head with RT field targeting the orbits. Patient 3: sagittal noncontrast CT of the spine with RT field targeting T11 through L3. Patient 12: axial noncontrast CT of the head with RT field targeting the right gangliocapsular area. (C) Images show sites of post-CART CNS relapse. Patient 1: sagittal positron emission tomography (PET)/CT showing [¹⁸F]fluorodeoxyglucose (FDG)-avid relapse in the brain, 1 month after CAR T-cell infusion (white arrow). Patient 3: sagittal PET/CT showing 2 FDG-avid sites of relapse at the margins of prior RT field, 1 month after CAR T-cell infusion (white arrows). Patient 12: axial postcontrast T1 MRI showing a left periventricular relapse, 5 months after CAR T-cell infusion (white arrows).](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/8/19/10.1182_bloodadvances.2024013393/1/blooda_adv-2024-013393-gr3.jpeg?Expires=1735805052&Signature=a4X9bd4vtURIpoStZIEV6ozDDnICBJgwEHM141HGXRXl~nyL9zuK0Q9O74z9v1SPJoUfQm3RasbjpyK~n0tnBiLSExLw3o3RbL2pBOF2STjzZVYL4lt0gt3nl0uHzmj1x5Q~ABMcbfzJy9Ig2OEG~h4E3jm3KH6hDU2EIfen-ahk7PiBd7hVQvASCGHlK0sDmCTw5jg~4T~zSrz8ZY478023ZJKhb5-vDTZS0IJOpY83aAVs6cag99kkRpu29mpCK5VJB9~DABDujh-ekwPztflrpz2rXoYeEszAQJ2MCoW1~jHgUTGzvcTuPiSt94wRRXOdXaRMa~wCvCh0SnRRQg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
CNS relapse. (A) The 12-month cumulative risk of CNS relapse after CNS-BRT and CART was 25.0% (95% CI, 6-52). (B) Images showing the CNS-BRT treatment plans to the 50% isodose line. Patient 1: sagittal postcontrast computed tomography (CT) of the head with RT field targeting the orbits. Patient 3: sagittal noncontrast CT of the spine with RT field targeting T11 through L3. Patient 12: axial noncontrast CT of the head with RT field targeting the right gangliocapsular area. (C) Images show sites of post-CART CNS relapse. Patient 1: sagittal positron emission tomography (PET)/CT showing [¹⁸F]fluorodeoxyglucose (FDG)-avid relapse in the brain, 1 month after CAR T-cell infusion (white arrow). Patient 3: sagittal PET/CT showing 2 FDG-avid sites of relapse at the margins of prior RT field, 1 month after CAR T-cell infusion (white arrows). Patient 12: axial postcontrast T1 MRI showing a left periventricular relapse, 5 months after CAR T-cell infusion (white arrows).
